Table 2. Relationship between characteristics and end-CCRT ΔNLR and end-AC ΔNLR.
| Variables | Increased ΔNLR at end-CCRT | Increased ΔNLR at end-AC | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | OR | aOR | 95% CI of aOR | P | n (%) | OR | aOR | 95% CI of aOR | P | ||
| Sex | 0.015 | 0.010 | |||||||||
| Female (ref.) | 23/33 (70) | 1.00 | 1.00 | 20 (61) | 1.00 | 1.00 | |||||
| Male | 43/48 (90) | 3.74 | 4.80 | 1.36–16.95 | 40 (83) | 3.25 | 4.45 | 1.43–13.79 | |||
| Age (years) | 0.213 | 0.032 | |||||||||
| > 51 (ref.) | 31/40 (78) | 1.00 | 1.00 | 26 (65) | 1.00 | 1.00 | |||||
| ≤ 51 | 35/41 (85) | 1.69 | 2.17 | 0.64–7.34 | 34 (83) | 2.62 | 3.45 | 1.11–10.75 | |||
| Cancer stage | 0.778 | 0.702 | |||||||||
| Stage II (ref.) | 13/21 (62) | 1.00 | 1.00 | 17 (81) | 1.00 | 1.00 | |||||
| Stage III | 31/38 (82) | 0.74 | 0.76 | 0.16–3.51 | 27 (71) | 0.58 | 0.59 | 0.15–2.33 | |||
| Stage IVA | 17/22 (77) | 0.57 | 0.38 | 0.07–2.08 | 16 (73) | 0.63 | 0.42 | 0.09–2.03 | |||
Abbreviations: ref., reference group; OR, odds ratio; aOR, adjusted odds ratio; 95%CI, 95% confidence interval